基因组
微生物群
生物
异型生物质的
计算生物学
肠道微生物群
人类微生物组计划
疾病
人类疾病
人类健康
人体微生物群
生物信息学
遗传学
医学
基因
环境卫生
生物化学
酶
病理
作者
Peter Spanogiannopoulos,Elizabeth N. Bess,Rachel N. Carmody,Peter J. Turnbaugh
标识
DOI:10.1038/nrmicro.2016.17
摘要
In this Review, Turnbaugh and colleagues discuss several mechanisms by which the human gut microbiome affects the metabolism of xenobiotics, including drugs and dietary compounds, and explore how this knowledge can be applied to improve the treatment of human disease. Although the importance of human genetic polymorphisms in therapeutic outcomes is well established, the role of our 'second genome' (the microbiome) has been largely overlooked. In this Review, we highlight recent studies that have shed light on the mechanisms that link the human gut microbiome to the efficacy and toxicity of xenobiotics, including drugs, dietary compounds and environmental toxins. Continued progress in this area could enable more precise tools for predicting patient responses and for the development of a new generation of therapeutics based on, or targeted at, the gut microbiome. Indeed, the admirable goal of precision medicine may require us to first understand the microbial pharmacists within.
科研通智能强力驱动
Strongly Powered by AbleSci AI